Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.

Autor: Moakes CA; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Bradbury AW; Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Abdali Z; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Bate GR; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Hall J; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Jarrett H; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Kelly L; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Kigozi J; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Lockyer S; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Meecham L; Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK., Patel S; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Popplewell M; Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Slinn G; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK., Deeks JJ; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.

Publikováno v: Health technology assessment (Winchester, England) [Health Technol Assess] 2024 Oct; Vol. 28 (65), pp. 1-72.

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.

Autor: Bradbury AW; University Department of Vascular Surgery, Solihull Hospital, University Hospitals Birmingham NHS Foundation Trust, Solihull, UK; Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: a.w.bradbury@bham.ac.uk., Moakes CA; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Popplewell M; Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK., Meecham L; Department of Vascular Surgery, University Hospital of Wales, Cardiff, UK., Bate GR; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Kelly L; Department of Vascular Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Chetter I; Hull York Medical School, University of Hull and University of York, York, UK., Diamantopoulos A; Department of Interventional Radiology, Guy's and St Thoma's NHS Foundation Trust, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK., Ganeshan A; Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Hall J; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Hobbs S; Department of Vascular Surgery, Dudley Group NHS Foundation Trust, Dudley, UK., Houlind K; Lillebaelt Hospital, University of Southern Denmark, Odense, Denmark., Jarrett H; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Lockyer S; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Malmstedt J; Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden; Division of Vascular Surgery, Department of Surgery, Södersjukhuset, Stockholm, Sweden., Patel JV; Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Patel S; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Rashid ST; Department of Vascular Surgery, Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust, Manchester, UK., Saratzis A; National Institute for Health and Care Research Leicester Biomedical Research Centre, University of Leicester, Leicester, UK., Slinn G; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Scott DJA; Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK., Zayed H; Department of Vascular Surgery, Guy's and St Thoma's NHS Foundation Trust, London, UK., Deeks JJ; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Publikováno v: Lancet (London, England) [Lancet] 2023 May 27; Vol. 401 (10390), pp. 1798-1809. Date of Electronic Publication: 2023 Apr 25.

Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.

Autor: Edwards NC; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.; Department of Cardiology, Green Lane Cardiovascular Unit, Auckland, New Zealand., Price AM; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.; Department of Nephrology, Queen Elizabeth Hospital, Birmingham, United Kingdom., Mehta S; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom., Hiemstra TF; Cambridge Clinical Trials Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom.; GlaxoSmithKline, England, United Kingdom., Kaur A; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom., Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Webb DJ; Center for Cardiovascular Science and Clinical Research Center, University of Edinburgh, United Kingdom., Dhaun N; Center for Cardiovascular Science and Clinical Research Center, University of Edinburgh, United Kingdom.; Department of Nephrology, National Health Services Lothian, Edinburgh, United Kingdom., MacIntyre IM; Center for Cardiovascular Science and Clinical Research Center, University of Edinburgh, United Kingdom.; Department of Nephrology, National Health Services Lothian, Edinburgh, United Kingdom., Farrah T; Center for Cardiovascular Science and Clinical Research Center, University of Edinburgh, United Kingdom.; Department of Nephrology, National Health Services Lothian, Edinburgh, United Kingdom., Melville V; Center for Cardiovascular Science and Clinical Research Center, University of Edinburgh, United Kingdom., Herrey AS; UCL Institute of Cardiovascular Science and Department of Cardiology, Barts Heart Centre, St Bartholomew's Hospital, London, United Kingdom., Slinn G; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom., Wale R; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom., Ives N; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom., Wheeler DC; Department of Renal Medicine, University College London, United Kingdom.; George Institute for Global Health, Sydney, Australia., Wilkinson I; Cambridge Clinical Trials Unit, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom.; GlaxoSmithKline, England, United Kingdom., Steeds RP; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.; Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom., Ferro CJ; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.; Department of Nephrology, Queen Elizabeth Hospital, Birmingham, United Kingdom., Townend JN; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.; Department of Cardiology, Queen Elizabeth Hospital Birmingham, United Kingdom.

Publikováno v: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2021 Oct; Vol. 16 (10), pp. 1491-1501. Date of Electronic Publication: 2021 Aug 30.

Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.

Autor: Crombie N; NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Doughty HA; NHS Blood and Transplant, Birmingham, UK., Bishop JRB; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Desai A; Pharmacy Department, Queen Elizabeth Hospital, Birmingham, UK., Dixon EF; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Hancox JM; West Midlands Ambulance Service NHS Trust, West Midlands, UK., Herbert MJ; Blood transfusion, The Royal Wolverhampton NHS Trust, Wolverhampton, UK., Leech C; The Air Ambulance Service, Blue Skies House, Butlers Leap, Rugby, UK., Lewis SJ; Magpas Air Ambulance, Huntingdon, UK., Nash MR; Midlands Air Ambulance and MERIT, West Midlands Ambulance Service NHS Trust, West Midlands, UK., Naumann DN; Institute of Inflammation and Aging, University of Birmingham, Birmingham, UK., Slinn G; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Smith H; NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Smith IM; NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Wale RK; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Wilson A; East Anglian Air Ambulance, Norwich, UK., Ives N; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Perkins GD; Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK; Critical Care Unit, Heartlands Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham. Electronic address: g.d.perkins@warwick.ac.uk.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2022 Apr; Vol. 9 (4), pp. e250-e261. Date of Electronic Publication: 2022 Mar 07.

An individual randomised efficacy trial of autologous blood products, leukocyte and platelet-rich fibrin (L-PRF), to promote ulcer healing in leprosy in Nepal: the TABLE trial protocol.

Autor: Napit IB; Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal. indran@TLMnepal.org., Shrestha D; Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal., Bishop J; Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Choudhury S; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Dulal S; Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal., Gill P; Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK., Gkini E; Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Gwyther H; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Hagge DA; Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal., Neupane K; Anandaban Hospital, The Leprosy Mission Nepal, Kathmandu, Nepal., Sartori J; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Slinn G; Birmingham Clinical Trials Unit, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Watson SI; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Lilford R; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Publikováno v: Trials [Trials] 2021 Jul 15; Vol. 22 (1), pp. 453. Date of Electronic Publication: 2021 Jul 15.